Mindmed collaborators dose first patient in phase 1 investigator-initiated trial of mdma-like substances

First-in-human trial to investigate the tolerability, pharmacology, and pharmacokinetics of novel mdma-like compounds versus a placebo in healthy subjects acute effects of equivalent doses will be compared across the following compounds: mdma, mda, lys-mdma and lys-mda new york , sept. 20, 2022 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (the "company" or "mindmed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the first patient has been dosed in a phase 1 investigator-initiated study led by mindmed collaborator prof.
MNMD Ratings Summary
MNMD Quant Ranking